Literature DB >> 26284591

Hepatocellular Carcinoma From Epidemiology to Prevention: Translating Knowledge into Practice.

Amit G Singal1, Hashem B El-Serag2.   

Abstract

The epidemiology of hepatocellular carcinoma (HCC) is characterized by dynamic temporal trends, several major established (i.e., HCV, HBV, alcohol) and emerging (i.e., diabetes, obesity, NAFLD) risk factors. Epidemiologic studies and clinical trials have identified additional demographic, clinical, pharmacological, genetic and life style factors that further affect or modify the likelihood of HCC and can be used in clinical practice to identify at-risk patients (i.e., risk stratification or prognostic algorithms) that can be targeted for prevention and early detection programs. These studies have also paved the way toward several well established preventive measures including HBV vaccination, HBV treatment, HCV treatment and HCC surveillance, and potential chemoprevention using statins, metformin or coffee. However, the effectiveness of HCC prevention in clinical practice and at the population level has lagged behind due to patient, provider, system, and societal factors. The Quality in the Continuum of Cancer Care model provides a framework for evaluating the HCC prevention processes, including potential failures that create a gap between efficacy and effectiveness.
Copyright © 2015 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Chemoprevention; Cirrhosis; Hepatitis B; Hepatitis C; NAFLD; Surveillance

Mesh:

Year:  2015        PMID: 26284591      PMCID: PMC4618036          DOI: 10.1016/j.cgh.2015.08.014

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  107 in total

1.  Efficacy, effectiveness, and comparative effectiveness in liver disease.

Authors:  Hashem B El-Serag; Jayant Talwalkar; W Ray Kim
Journal:  Hepatology       Date:  2010-08       Impact factor: 17.425

2.  Emerging trends in hepatocellular carcinoma incidence and mortality.

Authors:  Basile Njei; Yaron Rotman; Ivo Ditah; Joseph K Lim
Journal:  Hepatology       Date:  2014-11-24       Impact factor: 17.425

3.  Effectiveness of AFP and ultrasound tests on hepatocellular carcinoma mortality in HCV-infected patients in the USA.

Authors:  Hashem B El-Serag; Jennifer R Kramer; G John Chen; Zhigang Duan; Peter A Richardson; Jessica A Davila
Journal:  Gut       Date:  2011-01-21       Impact factor: 23.059

4.  Utilization of surveillance for hepatocellular carcinoma among hepatitis C virus-infected veterans in the United States.

Authors:  Jessica A Davila; Louise Henderson; Jennifer R Kramer; Fasiha Kanwal; Peter A Richardson; Zhigang Duan; Hashem B El-Serag
Journal:  Ann Intern Med       Date:  2011-01-18       Impact factor: 25.391

5.  Surveillance for hepatocellular carcinoma improves survival in Asian-American patients with hepatitis B: results from a community-based clinic.

Authors:  Myron J Tong; Hai-En Sun; Carlos Hsien; David S K Lu
Journal:  Dig Dis Sci       Date:  2009-12-04       Impact factor: 3.199

6.  A new laboratory-based algorithm to predict development of hepatocellular carcinoma in patients with hepatitis C and cirrhosis.

Authors:  Hashem B El-Serag; Fasiha Kanwal; Jessica A Davila; Jennifer Kramer; Peter Richardson
Journal:  Gastroenterology       Date:  2014-01-23       Impact factor: 22.682

7.  Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma.

Authors:  Jorge A Marrero; Ziding Feng; Yinghui Wang; Mindie H Nguyen; Alex S Befeler; Lewis R Roberts; K Rajender Reddy; Denise Harnois; Josep M Llovet; Daniel Normolle; Jackie Dalhgren; David Chia; Anna S Lok; Paul D Wagner; Sudhir Srivastava; Myron Schwartz
Journal:  Gastroenterology       Date:  2009-04-09       Impact factor: 22.682

8.  Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis.

Authors:  Valérie Paradis; Stéphane Zalinski; Emna Chelbi; Nathalie Guedj; Françoise Degos; Valérie Vilgrain; Pierre Bedossa; Jacques Belghiti
Journal:  Hepatology       Date:  2009-03       Impact factor: 17.425

9.  Meta-analysis: Treatment of hepatitis B infection reduces risk of hepatocellular carcinoma.

Authors:  J J Y Sung; K K F Tsoi; V W S Wong; K C T Li; H L Y Chan
Journal:  Aliment Pharmacol Ther       Date:  2008-07-24       Impact factor: 8.171

10.  Low risk of hepatocellular carcinoma in patients with primary sclerosing cholangitis with cirrhosis.

Authors:  Roman Zenouzi; Tobias J Weismüller; Peter Hübener; Kornelius Schulze; Michael Bubenheim; Nadine Pannicke; Christina Weiler-Normann; Henrike Lenzen; Michael P Manns; Ansgar W Lohse; Christoph Schramm
Journal:  Clin Gastroenterol Hepatol       Date:  2014-02-12       Impact factor: 11.382

View more
  185 in total

1.  Effect of travel distance and rurality of residence on initial surveillance for hepatocellular carcinoma in VA primary care patient with cirrhosis.

Authors:  Yolanda Rodriguez Villalvazo; Jennifer S McDanel; Lauren A Beste; Antonio J Sanchez; Mary Vaughan-Sarrazin; David A Katz
Journal:  Health Serv Res       Date:  2019-11-25       Impact factor: 3.402

Review 2.  Barriers to Disease Monitoring and Liver Cancer Surveillance Among Patients with Chronic Hepatitis B in the United States.

Authors:  Simona Ispas; Samuel So; Mehlika Toy
Journal:  J Community Health       Date:  2019-06

Review 3.  HCC: Transarterial Therapies-What the Interventional Radiologist Can Offer.

Authors:  Thomas J Vogl; Tatjana Gruber-Rouh
Journal:  Dig Dis Sci       Date:  2019-04       Impact factor: 3.199

Review 4.  Molecular Mechanisms Linking Nonalcoholic Steatohepatitis to Cancer.

Authors:  Kara Wegermann; Jeongeun Hyun; Anna Mae Diehl
Journal:  Clin Liver Dis (Hoboken)       Date:  2021-02-01

Review 5.  Racial Disparity in Gastrointestinal Cancer Risk.

Authors:  Hassan Ashktorab; Sonia S Kupfer; Hassan Brim; John M Carethers
Journal:  Gastroenterology       Date:  2017-08-12       Impact factor: 22.682

6.  GC7 blocks epithelial-mesenchymal transition and reverses hypoxia-induced chemotherapy resistance in hepatocellular carcinoma cells.

Authors:  Qing-Yun Zhou; Chao-Yong Tu; Chu-Xiao Shao; Wu-Ke Wang; Jing-De Zhu; Ying Cai; Jia-Yan Mao; Wei Chen
Journal:  Am J Transl Res       Date:  2017-05-15       Impact factor: 4.060

7.  Hepatic Stellate Cell-Macrophage Crosstalk in Liver Fibrosis and Carcinogenesis.

Authors:  Michitaka Matsuda; Ekihiro Seki
Journal:  Semin Liver Dis       Date:  2020-04-02       Impact factor: 6.115

8.  Biomarker analysis of fucosylated kininogen through depletion of lectin reactive heterophilic antibodies in hepatocellular carcinoma.

Authors:  Mengjun Wang; Jiabin Shen; Harmin Herrera; Amit Singal; Charles Swindell; Lu Renquan; Anand Mehta
Journal:  J Immunol Methods       Date:  2018-08-23       Impact factor: 2.303

9.  Reversal of multidrug resistance of hepatocellular carcinoma cells by metformin through inhibiting NF-κB gene transcription.

Authors:  Wei Wu; Jun-Ling Yang; Yi-Lang Wang; Han Wang; Min Yao; Li Wang; Juan-Juan Gu; Yin Cai; Yun Shi; Deng-Fu Yao
Journal:  World J Hepatol       Date:  2016-08-18

10.  miR-122 and miR-197 expressions in hepatic carcinoma patients before and after chemotherapy and their effect on patient prognosis.

Authors:  Gang Zhan; Hui Jiang; Rui Yang; Kai Yang
Journal:  Am J Transl Res       Date:  2021-06-15       Impact factor: 4.060

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.